OLANZAPINE VERSUS APREPITANT IN PATIENTS RECEIVING HIGH-EMETOGENIC CHEMOTHERAPY: INTERIM ANALYSIS OF RANDOMIZED PHASE II TRIAL | Zendy

A. А. Rumyantsev | Zendy; Elena Glazkova | Zendy; R. Yu. Nasyrova | Zendy; E. Ignatova | Zendy; L. V. Chitia | Zendy; А. С. Попова | Zendy; Х. Х.-М. Эльснукаева | Zendy; И. А. Покатаев | Zendy; Alexandra Tyulyandina | Zendy; М. Б. Стенина | Zendy; М. А. Фролова | Zendy; A. Bulanov | Zendy; V.Yu. Fedyanin | Zendy; O. Sekhina | Zendy; А. А. Tryakin | Zendy; Sergei Tjulandin | Zendy

Open Access

OLANZAPINE VERSUS APREPITANT IN PATIENTS RECEIVING HIGH-EMETOGENIC CHEMOTHERAPY: INTERIM ANALYSIS OF RANDOMIZED PHASE II TRIAL

Author(s) -

A. А. Rumyantsev,

Elena Glazkova,

R. Yu. Nasyrova,

E. Ignatova,

L. V. Chitia,

А. С. Попова,

Х. Х.-М. Эльснукаева,

И. А. Покатаев,

Alexandra Tyulyandina,

М. Б. Стенина,

М. А. Фролова,

A. Bulanov,

V.Yu. Fedyanin,

O. Sekhina,

А. А. Tryakin,

Sergei Tjulandin

Publication year - 2018

Publication title -

practical oncology

Language(s) - English

Resource type - Journals

eISSN - 1726-9830

pISSN - 1726-9814

DOI - 10.31917/1903419

Subject(s) - aprepitant , interim analysis , olanzapine , interim , nk1 receptor antagonist , medicine , randomized controlled trial , chemotherapy , oncology , antiemetic , psychiatry , political science , schizophrenia (object oriented programming) , law , receptor , substance p , neuropeptide

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research